Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
- None.
- None.
Insights
Evotec's partnership with the Crohn's & Colitis Foundation represents a strategic move to address critical gaps in the treatment of IBD, a chronic condition affecting millions globally. The focus on fibrosis and impaired intestinal barrier function is significant, as these are pivotal factors in the pathogenesis of IBD. Fibrosis can lead to complications like strictures and obstructions, while a compromised intestinal barrier can exacerbate inflammation and symptom severity.
Investing in these areas of research could yield therapies that not only manage symptoms but also alter disease progression, potentially improving patient outcomes and reducing healthcare costs. For stakeholders, this collaboration may enhance Evotec's pipeline, potentially leading to long-term value creation if successful therapies emerge. However, drug discovery is inherently risky and resource-intensive, with a high rate of attrition. Stakeholders should be aware that the benefits of this collaboration are speculative until clinical efficacy and safety are demonstrated.
Evotec's collaboration with a mission-driven foundation may offer financial advantages beyond the direct scope of drug discovery. Such partnerships can provide access to non-dilutive funding, which is advantageous for Evotec's capital structure. Additionally, the association with a reputable foundation can enhance Evotec's credibility and visibility in the biotech space, potentially attracting further partnerships or investment.
From an investor's perspective, it is essential to monitor Evotec's R&D efficiency and the progression of these targets through the drug development pipeline. Success in these early stages can lead to significant future revenues, but the timeline for drug development is long and returns are uncertain. Investors should consider this collaboration as part of Evotec's broader strategy and not as an immediate revenue driver.
The IBD market is experiencing a growing demand for innovative treatments due to the chronic nature of the diseases and the lack of curative therapies. Evotec's collaboration is timely, as it aligns with the market's need for drugs that address the underlying pathophysiology of IBD, rather than just symptom management.
Market trends show a significant push towards personalized medicine and treatments that offer improved safety profiles and efficacy. If Evotec's drug targets prove to be successful, they could capture a significant share of the IBD market, which is projected to grow in the coming years. It is essential for Evotec to maintain a competitive edge by investing in robust R&D and fostering collaborations that leverage their integrated platform to expedite drug discovery.
- EVOTEC JOINS FORCES WITH THE CROHN'S & COLITIS FOUNDATION'S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE ("IBD")
- THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIRED INTESTINAL BARRIER FUNCTION
HAMBURG, GERMANY and NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that the Company has joined forces with the Crohn's & Colitis Foundation ("the Foundation"), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease ("IBD"), which includes Crohn's disease and ulcerative colitis.
Under the collaboration, Evotec joins forces with the Foundation's IBD Therapeutics Incubator programme that facilitates collaboration between the Foundation, academic researchers, and industry partners to translate groundbreaking basic research that was performed by academic researchers and identified by the Foundation into medical innovations for IBD patients.
The collaboration leverages Evotec's end-to-end integrated R&D platform to advance drug discovery for two innovative drug targets that address major unmet medical needs of patients with Crohn's disease and ulcerative colitis: Fibrosis, the excessive accumulation of scar tissue in the intestinal wall, and impaired intestinal barrier function, which leads to increased intestinal permeability, also known as "leaky gut".
Dr Matthias Evers, Chief Business Officer of Evotec, commented: "Mission-driven foundations like the Crohn's & Colitis Foundation are an essential part of the healthcare ecosystem as they drive medical progress in areas of significant unmet need that would otherwise not be pursued. As we join forces within the Foundation in this second collaboration, we are fully aligned on our mission to create access to novel therapeutics and look forward to leveraging both Evotec's translational experience as well as our fully integrated drug discovery powerhouse within the Foundation's IBD Therapeutics Incubator."
"We are excited about this collaboration with Evotec as part of the Foundation's IBD Therapeutics Incubator because it will transform ideas to therapeutic product opportunities and scientific research into patient solutions," said Andrés Hurtado Lorenzo, PhD, Senior Vice President, Translational Research & IBD Ventures at the Crohn's & Colitis Foundation. "We're actually driving research from idea to therapeutic product opportunity."
"We're excited to initiate these drug discovery projects with top-notch academic investigators and the experienced scientists at Evotec," said Jennifer Swantek, PhD, Director of the Foundation's IBD Therapeutics Incubator programme. "We're eager to deliver much needed, differentiated therapies to Crohn's disease and ulcerative colitis patients as soon as possible."
No financial terms of the collaboration were disclosed.
About IBD
Nearly 1 in 100 Americans have IBD, a serious chronic medical condition that indicates chronic inflammation of the gastrointestinal tract. IBD symptoms, which can include abdominal pain and diarrhoea can be mild or severe, and they may appear suddenly or come on gradually. Crohn's disease and ulcerative colitis are debilitating chronic conditions. Even with proper medication and diet, as many as 2/3 to 3/4 of people with Crohn's disease will require surgery at some point in their lives. The mission of the Crohn's & Colitis Foundation is to cure Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease ("IBD"), and to improve the quality of life of children and adults affected by these diseases. The Foundation has invested nearly
ABOUT THE CROHN'S & COLITIS FOUNDATION
The Crohn's & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for IBD, with the mission of curing Crohn's disease and ulcerative colitis and improving the quality of life for the millions of Americans living with IBD. The Foundation's work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org.
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications, Hinnerk.Rohwedder@evotec.com
IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the collaboration between Evotec SE and the Crohn's & Colitis Foundation?
What are the specific medical needs being addressed by the collaboration?
What is Evotec SE's role in the collaboration?
Who is Dr. Matthias Evers and what is his role in the collaboration?
